Logo image of AVR

ANTERIS TECHNOLOGIES GLOBAL (AVR) Stock Fundamental Analysis

NASDAQ:AVR - Nasdaq - US03675P1021 - Common Stock - Currency: USD

4.98  -0.16 (-3.11%)

After market: 4.98 0 (0%)

Fundamental Rating

1

Overall AVR gets a fundamental rating of 1 out of 10. We evaluated AVR against 191 industry peers in the Health Care Equipment & Supplies industry. AVR has a bad profitability rating. Also its financial health evaluation is rather negative. AVR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AVR has reported negative net income.
In the past year AVR has reported a negative cash flow from operations.
AVR Yearly Net Income VS EBIT VS OCF VS FCFAVR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -10M -20M -30M -40M

1.2 Ratios

AVR has a Return On Assets of -218.09%. This is amonst the worse of the industry: AVR underperforms 92.15% of its industry peers.
AVR has a worse Return On Equity (-1461.24%) than 87.96% of its industry peers.
Industry RankSector Rank
ROA -218.09%
ROE -1461.24%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVR Yearly ROA, ROE, ROICAVR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 -100 -200 -300

1.3 Margins

AVR has a Gross Margin of 32.06%. This is in the lower half of the industry: AVR underperforms 72.77% of its industry peers.
AVR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVR Yearly Profit, Operating, Gross MarginsAVR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

AVR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVR has about the same amount of shares outstanding.
The debt/assets ratio for AVR has been reduced compared to a year ago.
AVR Yearly Shares OutstandingAVR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M
AVR Yearly Total Debt VS Total AssetsAVR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -18.23, we must say that AVR is in the distress zone and has some risk of bankruptcy.
AVR has a Altman-Z score of -18.23. This is amonst the worse of the industry: AVR underperforms 86.39% of its industry peers.
AVR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.02, AVR is doing good in the industry, outperforming 68.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -18.23
ROIC/WACCN/A
WACC9.04%
AVR Yearly LT Debt VS Equity VS FCFAVR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 10M -10M -20M -30M

2.3 Liquidity

AVR has a Current Ratio of 0.93. This is a bad value and indicates that AVR is not financially healthy enough and could expect problems in meeting its short term obligations.
AVR has a Current ratio of 0.93. This is amonst the worse of the industry: AVR underperforms 89.01% of its industry peers.
A Quick Ratio of 0.90 indicates that AVR may have some problems paying its short term obligations.
AVR's Quick ratio of 0.90 is on the low side compared to the rest of the industry. AVR is outperformed by 79.06% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.9
AVR Yearly Current Assets VS Current LiabilitesAVR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 5M 10M 15M 20M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for AVR have decreased strongly by -50.58% in the last year.
Looking at the last year, AVR shows a very negative growth in Revenue. The Revenue has decreased by -14.56% in the last year.
EPS 1Y (TTM)-50.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.38%
Revenue 1Y (TTM)-14.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%28.38%

3.2 Future

AVR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.10% yearly.
Based on estimates for the next years, AVR will show a very strong growth in Revenue. The Revenue will grow by 36.01% on average per year.
EPS Next Y-130.32%
EPS Next 2Y-21.88%
EPS Next 3Y-12.95%
EPS Next 5Y-6.1%
Revenue Next Year8.02%
Revenue Next 2Y13.14%
Revenue Next 3Y57.44%
Revenue Next 5Y36.01%

3.3 Evolution

AVR Yearly Revenue VS EstimatesAVR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
AVR Yearly EPS VS EstimatesAVR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVR Price Earnings VS Forward Price EarningsAVR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVR Per share dataAVR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A cheap valuation may be justified as AVR's earnings are expected to decrease with -12.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.88%
EPS Next 3Y-12.95%

More info and screens

0

5. Dividend

5.1 Amount

AVR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANTERIS TECHNOLOGIES GLOBAL

NASDAQ:AVR (4/25/2025, 8:00:01 PM)

After market: 4.98 0 (0%)

4.98

-0.16 (-3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners39.23%
Inst Owner Change0.08%
Ins Owners7.63%
Ins Owner Change100%
Market Cap179.38M
Analysts80
Price Target16.83 (237.95%)
Short Float %1.59%
Short Ratio1.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 65.59
P/FCF N/A
P/OCF N/A
P/B 56.95
P/tB 62.18
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0.08
BVpS0.09
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -218.09%
ROE -1461.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.06%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 169.52%
Cap/Sales 86.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.9
Altman-Z -18.23
F-ScoreN/A
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.38%
EPS Next Y-130.32%
EPS Next 2Y-21.88%
EPS Next 3Y-12.95%
EPS Next 5Y-6.1%
Revenue 1Y (TTM)-14.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%28.38%
Revenue Next Year8.02%
Revenue Next 2Y13.14%
Revenue Next 3Y57.44%
Revenue Next 5Y36.01%
EBIT growth 1Y-45.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.26%
EBIT Next 3Y-8.48%
EBIT Next 5Y-5.17%
FCF growth 1Y-19.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.73%
OCF growth 3YN/A
OCF growth 5YN/A